GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)
India
· Delayed Price · Currency is INR 2,788.70
+67.20 (2.47%)
May 13, 2025, 3:29 PM IST
NSE:GLAXO Revenue
In the fiscal year ending March 31, 2025, GlaxoSmithKline Pharmaceuticals had annual revenue of 38.95B INR with 12.78% growth. GlaxoSmithKline Pharmaceuticals had revenue of 10.15B in the quarter ending March 31, 2025, with 9.17% growth.
Revenue
38.95B
Revenue Growth
+12.78%
P/S Ratio
12.44
Revenue / Employee
11.54M
Employees
3,211
Market Cap
461.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 38.95B | 4.41B | 12.78% |
| Mar 31, 2024 | 34.54B | 2.02B | 6.21% |
| Mar 31, 2023 | 32.52B | -263.06M | -0.80% |
| Mar 31, 2022 | 32.78B | 3.52B | 12.05% |
| Mar 31, 2021 | 29.26B | -2.99B | -9.27% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
GlaxoSmithKline Pharmaceuticals News
- 3 months ago - GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) Q3 2025 Earnings Call Highlights: Strong ... - GuruFocus
- 3 months ago - Q3 2025 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript - GuruFocus
- 6 months ago - GSK Pharma sets record date for Rs 12 special interim dividend on November 7, 2024 - Business Upturn